JPMorgan initiated coverage of Omada Health (OMDA) with an Overweight rating and $19 price target Omada offers a “between care” patient monitoring program that combines human-led clinical care with technology to drive behavioral change and it has “ample room to grow in an underpenetrated chronic disease market,” the analyst tells investors. The firm models a roughly 24% compound annual growth rate over the next three years and EBITDA profitability in 2027, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health initiated with an Overweight at Morgan Stanley
- Omada Health initiated with a Buy at Goldman Sachs
- JPMorgan Issues Buy Rating for Omada Health, Inc. Citing Growth Potential in Underpenetrated $135 Billion Market and Strategic Partnerships
- Omada Health: A Compelling Investment Opportunity in Digital Health with Strong Growth Potential
- Omada Health: Strong Growth Prospects and Path to Profitability with Undervalued Potential